Clincosm LogoSign in Get a demo

Functional Proteomics of Alveolar Macrophages

Sponsor
Ohio State University (Other)
Overall Status
Completed
CT.gov ID
NCT00806091
Collaborator
(none)
72
Enrollment
1
Location
53
Duration (Months)
1.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to obtain young white blood cells (monocytes) from the investigators donated blood for research into how these cells change into large, mature white blood cells (macrophages) and how smoking causes Chronic Obstructive Pulmonary Disease (COPD).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Our research goal is to identify new targets and strategies to help care for patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic airway inflammatory disorder characterized by a progressive loss of pulmonary function. Mononuclear phagocytes are known to be critically involved in both repair/remodeling and destructive events in COPD. Although smoking is the chief environmental risk factor for COPD, the molecular details responsible for the genesis and progression of smoking-mediated COPD require further investigation. In searching for new knowledge and research strategies for this challenging topic, we have made substantial progress in mononuclear phagocyte proteomics and laid the groundwork for this translational research of COPD.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    72 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Functional Proteomics of Alveolar Macrophages
    Study Start Date :
    Jul 1, 2004
    Actual Primary Completion Date :
    Sep 1, 2008
    Actual Study Completion Date :
    Dec 1, 2008

    Arms and Interventions

    Arm Intervention/Treatment
    COPD subjects

    healthy subjects

    Outcome Measures

    Primary Outcome Measures

    1. to define AM's pathogenic pathways underlying the development of COPD [end of study]

    Secondary Outcome Measures

    1. to determine protein polymorphism(s) that impact genetic susceptibility to COPD [end of study]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • COPD, smoker

    • COPD, non smoker

    Exclusion Criteria:
    • none

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Ohio State University Columbus Ohio United States 43210

    Sponsors and Collaborators

    • Ohio State University

    Investigators

    • Principal Investigator: Haifeng Wu, MD, Ohio State University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Philip Diaz, Professor of Internal Medicine, Ohio State University
    ClinicalTrials.gov Identifier:
    NCT00806091
    Other Study ID Numbers:
    • 2004H0102
    First Posted:
    Dec 10, 2008
    Last Update Posted:
    Nov 1, 2021
    Last Verified:
    Oct 1, 2021
    Keywords provided by Philip Diaz, Professor of Internal Medicine, Ohio State University
    AM proteomes will be compared between smokers with and without COPD

    Study Results

    No Results Posted as of Nov 1, 2021